Literature DB >> 15446315

Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology.

Brian J Nankivell1, Richard J Borrows, Caroline L S Fung, Philip J O'Connell, Jeremy R Chapman, Richard D M Allen.   

Abstract

BACKGROUND: The role and burden of cyclosporine (CsA) nephrotoxicity in long-term progressive kidney graft dysfunction is poorly documented.
METHODS: The authors evaluated 888 prospective protocol kidney biopsy specimens from 99 patients taken regularly until 10 years after transplantation for evidence of CsA nephrotoxicity.
RESULTS: The most sensitive histologic marker of CsA nephrotoxicity was arteriolar hyalinosis, predicted by CsA dose and functional CsA nephrotoxicity. Striped fibrosis was associated with early initiation of CsA and the need for posttransplant dialysis (both P < 0.05). The 10-year cumulative Kaplan-Meier prevalence of arteriolar hyalinosis, striped fibrosis, and tubular microcalcification was 100%, 88.0%, and 79.2% of kidneys, respectively. Beyond 1 year, 53.9% had two or more lesions of CsA nephrotoxicity. Structural CsA nephrotoxicity occurred in two phases, with different clinical and histologic characteristics. The acute phase occurred with a median onset 6 months after transplantation, was usually reversible, and was associated with functional CsA nephrotoxicity (P < 0.05), high CsA levels (P < 0.05), and mild arteriolar hyalinosis (P < 0.001). The chronic phase of CsA nephrotoxicity persisted over several biopsies, occurred at a median onset of 3 years, and was associated with lower CsA doses and trough levels (both P < 0.05). It was largely irreversible and accompanied by severe arteriolar hyalinosis and progressive glomerulosclerosis (both P < 0.001). A threshold CsA dose of 5 mg/kg/day predicted worsening of arteriolar hyalinosis on sequential histology.
CONCLUSIONS: Pathologic changes of CsA nephrotoxicity were virtually universal by 10 years and exacerbated chronic allograft nephropathy. CsA is unsuitable as a universal, long-term immunosuppressive agent for kidney transplantation. Strategies to ameliorate or avoid nephrotoxicity are thus urgently needed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15446315     DOI: 10.1097/01.tp.0000128636.70499.6e

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  85 in total

1.  Periodontitis case definition affects the association with renal function in kidney transplant recipients.

Authors:  E Ioannidou; M Shaqman; J Burleson; A Dongari-Bagtzoglou
Journal:  Oral Dis       Date:  2010-10       Impact factor: 3.511

2.  Renal Graft Fibrosis and Inflammation Quantification by an Automated Fourier-Transform Infrared Imaging Technique.

Authors:  Vincent Vuiblet; Michael Fere; Cyril Gobinet; Philippe Birembaut; Olivier Piot; Philippe Rieu
Journal:  J Am Soc Nephrol       Date:  2015-12-18       Impact factor: 10.121

Review 3.  Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data.

Authors:  Angela C Webster; Rebecca C Woodroffe; Rod S Taylor; Jeremy R Chapman; Jonathan C Craig
Journal:  BMJ       Date:  2005-09-12

Review 4.  Chronic allograft nephropathy in paediatric renal transplantation.

Authors:  Stephen I Alexander; Jeffrey T Fletcher; Brian Nankivell
Journal:  Pediatr Nephrol       Date:  2006-08-30       Impact factor: 3.714

5.  The epoxyeicosatrienoic acid analog PVPA ameliorates cyclosporine-induced hypertension and renal injury in rats.

Authors:  Michael M Yeboah; Md Abdul Hye Khan; Marla A Chesnik; Amit Sharma; Mahesh P Paudyal; John R Falck; John D Imig
Journal:  Am J Physiol Renal Physiol       Date:  2016-06-29

6.  Relationships among injury, fibrosis, and time in human kidney transplants.

Authors:  Jeffery M Venner; Konrad S Famulski; Jeff Reeve; Jessica Chang; Philip F Halloran
Journal:  JCI Insight       Date:  2016-01-21

7.  RGS4 controls renal blood flow and inhibits cyclosporine-mediated nephrotoxicity.

Authors:  A Siedlecki; J R Anderson; X Jin; J R Garbow; T S Lupu; A J Muslin
Journal:  Am J Transplant       Date:  2009-12-02       Impact factor: 8.086

Review 8.  Through a glass darkly: seeking clarity in preventing late kidney transplant failure.

Authors:  Mark D Stegall; Robert S Gaston; Fernando G Cosio; Arthur Matas
Journal:  J Am Soc Nephrol       Date:  2014-08-05       Impact factor: 10.121

Review 9.  The Kidney in Pediatric Liver Disease.

Authors:  Robyn Greenfield Matloff; Ronen Arnon
Journal:  Curr Gastroenterol Rep       Date:  2015-09

10.  Donor ABCB1 variant associates with increased risk for kidney allograft failure.

Authors:  Jason Moore; Amy Jayne McKnight; Bernd Döhler; Matthew J Simmonds; Aisling E Courtney; Oliver J Brand; David Briggs; Simon Ball; Paul Cockwell; Christopher C Patterson; Alexander P Maxwell; Stephen C L Gough; Gerhard Opelz; Richard Borrows
Journal:  J Am Soc Nephrol       Date:  2012-10-11       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.